vandetanib   Click here for help

GtoPdb Ligand ID: 5717

Synonyms: Caprelsa® | CH 331 | ZD 6474 | ZD-6474 | ZD6474
Approved drug PDB Ligand
vandetanib is an approved drug (FDA (2011), EMA (2012))
Compound class: Synthetic organic
Comment: Vandetanib is a Type-1 kinase inhibitor. It potently inhibits RET, VEGFR-2 (KDR) and EGFR tyrosine kinase activity [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 1
Rotatable bonds 6
Topological polar surface area 59.51
Molecular weight 474.11
XLogP 4.14
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COc1cc2c(ncnc2cc1OCC1CCN(CC1)C)Nc1ccc(cc1F)Br
Isomeric SMILES COc1cc2c(ncnc2cc1OCC1CCN(CC1)C)Nc1ccc(cc1F)Br
InChI InChI=1S/C22H24BrFN4O2/c1-28-7-5-14(6-8-28)12-30-21-11-19-16(10-20(21)29-2)22(26-13-25-19)27-18-4-3-15(23)9-17(18)24/h3-4,9-11,13-14H,5-8,12H2,1-2H3,(H,25,26,27)
InChI Key UHTHHESEBZOYNR-UHFFFAOYSA-N
Selectivity at catalytic receptors
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
ret proto-oncogene Primary target of this compound Hs Inhibitor Inhibition 7.5 pKd - 3
pKd 7.5 (Kd 3.4x10-8 M) [3]
kinase insert domain receptor Primary target of this compound Hs Inhibitor Inhibition 8.0 pIC50 - 5
pIC50 8.0 (IC50 9x10-9 M) [5]
ret proto-oncogene Primary target of this compound Hs Inhibitor Inhibition 7.0 – 8.4 pIC50 - 2,6
pIC50 8.4 (IC50 4x10-9 M) [6]
Description: In a biochemical assay.
pIC50 7.0 (IC50 1x10-7 M) [2]
epidermal growth factor receptor Hs Inhibitor Inhibition 6.5 pIC50 - 2
pIC50 6.5 (IC50 3x10-7 M) [2]